Mobenakin

From Food & Medicine Encyclopedia

Mobenakin

Mobenakin is a pharmaceutical compound used primarily in the treatment of certain cardiovascular conditions. It is classified as a beta-blocker, which functions by blocking the effects of epinephrine (adrenaline) on the heart and blood vessels, thereby reducing heart rate, blood pressure, and strain on the heart.

Pharmacology[edit]

Mobenakin works by selectively inhibiting beta-1 adrenergic receptors in the heart. This action decreases the heart rate and contractility, leading to a reduction in cardiac output and blood pressure. Unlike non-selective beta-blockers, Mobenakin has a higher affinity for beta-1 receptors, which are predominantly found in cardiac tissue, thus minimizing the risk of bronchoconstriction in patients with respiratory conditions.

Indications[edit]

Mobenakin is indicated for the management of:

  • Hypertension (high blood pressure)
  • Angina pectoris (chest pain)
  • Heart failure
  • Arrhythmias (irregular heartbeats)

Contraindications[edit]

Mobenakin should not be used in patients with:

  • Severe bradycardia (slow heart rate)
  • Heart block greater than first degree
  • Cardiogenic shock
  • Decompensated heart failure

Side Effects[edit]

Common side effects of Mobenakin include:

  • Fatigue
  • Dizziness
  • Cold extremities
  • Bradycardia

Less common but serious side effects may include:

  • Heart block
  • Worsening of heart failure
  • Bronchospasm

Dosage and Administration[edit]

Mobenakin is typically administered orally, with the dosage adjusted based on the patient's response and clinical condition. It is important to start with a low dose and titrate gradually to minimize the risk of adverse effects.

Mechanism of Action[edit]

Mobenakin's primary mechanism involves the competitive antagonism of catecholamines at beta-1 adrenergic receptors. This leads to decreased cyclic AMP levels, reduced calcium influx, and ultimately, decreased myocardial contractility and heart rate.

Research and Development[edit]

Mobenakin was developed in the late 20th century as part of a new generation of cardioselective beta-blockers. Ongoing research is focused on its potential benefits in reducing cardiovascular events in high-risk populations.

Also see[edit]


Mobenakin
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG



Cardiovascular disease A-Z

Most common cardiac diseases

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

A[edit]

B[edit]

C[edit]

D[edit]

E[edit]

H[edit]

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

I[edit]

K[edit]

L[edit]

M[edit]

N[edit]

O[edit]

P[edit]

R[edit]

S[edit]

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z

T[edit]

V[edit]

W[edit]

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=Mobenakin&oldid=6024303"